Overview

Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Status:
Unknown status

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The clinical hypothesis of this study is that the addition of Panitumumab to the first line treatment combination of docetaxel plus cisplatin will provide benefit to patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Gallego de Investigaciones Oncologicas

Collaborators:

Amgen
Trial Form Support S.L.

Treatments:

Antibodies, Monoclonal
Cisplatin
Docetaxel
Panitumumab